Aelian Biotechnology combines CRISPR screening with single-cell sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions of drugs.
CRISPR screening has revolutionized the unbiased annotation of gene function, but most screens done so far have been confined to rather simplistic read-outs (usually life/death of the target cells). Combining CRISPR perturbation with single-cell sequencing allows researchers to assess much more complex phenotypes, thus effectively broadening the scope of these screens. At Aelian, we use the CRISPR single-cell screening technology to perturb cells with CRISPR and profile transcriptional outcomes by RNA sequencing at single-cell resolution. Importantly, our technology is applicable across a wide range of cell types and also works in primary cells.
Thomas has extensive experience in financing and corporate development of start-up companies. In his previous position, he was founding CEO of Haplogen Genomics GmbH, a very successful Austrian life science company sold to Horizon Discovery plc in 2015, and after the acquisition Vice President Products at Horizon, responsible for gene-engineered cell line products and global Head of Corporate Strategy and Compliance. Before he served as managing partner at Pontis Capital for 13 years and had several positions in the area of business development, financing and licensing.
Tilmann is a highly creative thinker with 20+ publications and 10+ patent applications. Together with Thomas he was part of the Haplogen Genomics management team, his scientific and technical knowledge was key for the successful exit to Horizon. At Horizon, Tilmann recently served as their Head of Innovation with global responsibility and oversight of all ongoing R&D projects.
Christoph is a principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences. His research focuses on developing high-throughput technologies for biomedical applications. He is also a guest professor at the Medical University of Vienna, scientific coordinator of the Biomedical Sequencing Facility at CeMM, and adjunct group leader for bioinformatics at the Max Planck Institute for Informatics. He has received several research awards, including the Max Planck Society’s Otto Hahn Medal (2009), an ERC Starting Grant (2016-2021), and the Overton Prize of the International Society of Computational Biology (2017).
At Aelian Biotechnology we strive to develop market leading products and services in the area of CRISPR single-cell screening. We invite you to be a part of something bigger than yourself. If you want to join a young team and work with passion, courage and integrity please consider applying for one of these open job positions.
Currently we have no open positions.
Campus-Vienna-Biocenter 3, Landstraße, Wien 1030, Austria